The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury
Abstract
Background: Liver injury is a common complication of anti-tuberculosis therapy. N-acetylcysteine (NAC) used in patients with paracetamol toxicity with limited evidence of benefit in liver injury due to other causes. Methods: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy of intravenous NAC in hospitalized adult patients with anti-tuberculosis drug–induced liver injury (AT-DILI). The primary endpoint was time for serum alanine aminotransferase (ALT) to fall below 100 U/L. Secondary endpoints included length of hospital stay, in-hospital mortality, and adverse events. Results: Fifty-three participants were randomized to NAC and 49 to placebo. Mean age was 38 (SD±10) years, 58 (57%) were female, 89 (87%) were HIV positive. Median (IQR) serum ALT and bilirubin at presentation were 462 (266–790) U/L and 56 (25–100) μmol/L, respectively. Median time to ALT <100 U/L was 7.5 (6–11) days in the NAC arm and 8 (5–13) days in the placebo arm. Median time to hospital discharge was shorter in the NAC arm (9 [6–15] days) than in the placebo arm (18 [10–25] days) (HR, 1.73; 95% CI, 1.13–2.65). Mortality was 14% overall and did not differ by study arm. The study infusion was stopped early due to an adverse reaction in 5 participants receiving NAC (nausea and vomiting [3], anaphylaxis [1], pain at drip site [1]). Conclusions: NAC did not shorten time to ALT <100 U/L in participants with AT-DILI, but significantly reduced length of hospital stay. NAC should be considered in management of AT-DILI. Clinical Trials Registration: South African National Clinical Trials Registry (SANCTR: DOH-27-0414-4719).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another trial including 102 patients with DILI due to antituberculosis medications reported a shorter length of stay, but no survival benefit with NAC.[20]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [20]
In the citing paper
“Another randomized trial of 102 patients with antitubercular DILI also demonstrated a shorter length of stay but no survival benefit with NAC.149”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [149]
Citations
Cites
Interventions for paracetamol (acetaminophen) overdose
Chiew, A. L., Gluud, C., Brok, J., & Buckley, N. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003328.pub3 · Cited by 170
Green, J., Heard, K., Reynolds, K., & Albert, D. (2013) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2012.4.6885 · Cited by 135
Research works printed but not linked: 26
- Tostmann, 2008, Antituberculosis drug-induced hepatotoxicity: concise up-to-date review, J Gastroenterol Hepatol, 23, 192, 10.1111/j.1440-1746.2007.05207.x · DOI · Paper page
- Abbara, 2017, Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK, BMC Infect Dis, 17, 231, 10.1186/s12879-017-2330-z · DOI · Paper page
- Devarbhavi, 2013, Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury, J Gastroenterol Hepatol, 28, 161, 10.1111/j.1440-1746.2012.07279.x · DOI · Paper page
- Schutz, 2012, Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa, S Afr Med J, 102, 506, 10.7196/SAMJ.5650 · DOI
- Saukkonen, 2006, An official ATS statement: hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 174, 935, 10.1164/rccm.200510-1666ST · DOI · Paper page
- Rank, 2000, N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study, Crit Care Med, 28, 3799, 10.1097/00003246-200012000-00006 · DOI · Paper page
- Shi, 2005, A multi-center clinical study of N-acetylcysteine on chronic hepatitis B, Zhonghua Gan Zang Bing Za Zhi, 13, 20
- Darweesh, 2017, Effect of N-acetylcysteine on mortality and liver transplantation rate in non-acetaminophen-induced acute liver failure: a multicenter study, Clin Drug Investig, 37, 473, 10.1007/s40261-017-0505-4 · DOI
- Lee, 2009, Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
- Chughlay, 2016, N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review, Br J Clin Pharmacol, 81, 1021, 10.1111/bcp.12880 · DOI
- Attri, 2000, Isoniazid- and rifampicin-induced oxidative hepatic injury—protection by N-acetylcysteine, Hum Exp Toxicol, 19, 517, 10.1191/096032700674230830 · DOI
- Singh, 2012, Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model, Hum Exp Toxicol, 31, 788, 10.1177/0960327111433901 · DOI
- Baniasadi, 2010, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, Eur J Gastroenterol Hepatol, 22, 1235, 10.1097/MEG.0b013e32833aa11b · DOI
- Polson, 2005, AASLD position paper: the management of acute liver failure, Hepatology, 41, 1179, 10.1002/hep.20703 · DOI · Paper page
- Vilstrup, 2014, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 · DOI · Paper page
- Sharma Surendra, 2010, Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment–induced hepatotoxicity, Clin Infect Dis, 50, 833, 10.1086/650576 · DOI
- World Medical Association, 2013, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, 310, 2191, 10.1001/jama.2013.281053 · DOI · Paper page
- Metushi, 2016, Mechanism of isoniazid-induced hepatotoxicity: then and now, Br J Clin Pharmacol, 81, 1030, 10.1111/bcp.12885 · DOI · Paper page
- McGill, 2016, The past and present of serum aminotransferases and the future of liver injury biomarkers, EXCLI J, 15, 817
- Lindblom, 2007, Isoforms of alanine aminotransferases in human tissues and serum—differential tissue expression using novel antibodies, Arch Biochem Biophys, 466, 66, 10.1016/j.abb.2007.07.023 · DOI
- Sanjay, 2017, Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury, Eur J Clin Pharmacol, 73, 399, 10.1007/s00228-016-2183-1 · DOI
- Thulin, 2014, Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts, Liver Int, 34, 367, 10.1111/liv.12322 · DOI · Paper page
- Li, 2014, MicroRNAs in drug-induced liver injury, J Clin Transl Hepatol, 2, 162
- Hummelen, 2010, Micronutrients, N-acetyl cysteine, probiotics and prebiotics, a review of effectiveness in reducing HIV progression, Nutrients, 2, 626, 10.3390/nu2060626 · DOI
- Amaral, 2016, N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions, BMC Microbiol, 16, 251, 10.1186/s12866-016-0872-7 · DOI
- Teskey, 2018, The synergistic effects of the glutathione precursor, NAC and first-line antibiotics in the granulomatous response against Mycobacterium tuberculosis, Front Immunol, 9, 2069, 10.3389/fimmu.2018.02069 · DOI
Cited by
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Sanabria-Cabrera, J., Tabbai, S., Niu, H., Alvarez-Alvarez, I., Licata, A., Björnsson, E., Andrade, R. J., & Lucena, M. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876868 · Cited by 54
Metadata
- Authors
- Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., Hickman, N., Stewart, A., Sonderup, M., Spearman, C. W., & Cohen, K.
- Affiliations
- Department of Medicine, University of Cape Town, Cape Town, South Africa
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- Division of Gastroenterology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa
- Clinical Research Centre, University of Cape Town, Cape Town, South Africa
- Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- ORCID
- Maartens, Gary
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-26
- Volume
- 73
- Issue
- 9
- Pages
- e3377-e3383
- ISSN
- 1058-4838
- 1537-6591
- Cited by
- 46
- References
- 2
- Language
- en
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- South African Medical Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. https://app.cochat.ai/papers/10.1093/cid/ciaa1255
- The paper
- Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., Hickman, N., Stewart, A., Sonderup, M., Spearman, C. W., & Cohen, K. (2021). A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.